ABSTRACT
Objectives To evaluate the effectiveness of widespread adoption of masks or face coverings to reduce community transmission of the SARS-CoV-2 virus that causes Covid-19.
Methods We employed an agent-based stochastic network simulation model, where Covid-19 progresses across census tracts according to a variant of SEIR. We considered a mask order that was initiated 3.5 months after the first confirmed Covid-19 case. We evaluated scenarios where wearing a mask reduces transmission and susceptibility by 50% or 80%; an individual wears a mask with a probability of 0%, 20%, 40%, 60%, 80%, or 100%.
Results If 60% of the population wears masks that are 50% effective, this decreases the cumulative infection attack rate (CAR) by 25%, the peak prevalence by 51%, and the population mortality by 25%. If 100% of people wear masks (or 60% wear masks that are 80% effective), this decreases the CAR by 38%, the peak prevalence by 67%, and the population mortality by 40%.
Conclusions After community transmission is present, masks can significantly reduce infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Financial support for this study was provided in part by a grant from several sources from state universities including NC TrCS at the University of North Carolina at Chapel Hill, NC State University, and the Fitts Department of Industrial and Systems Engineering. It also received partial support from alumni donations at NC State University and Georgia Institute of Technology. The funding agreement ensured the independence of the authors in designing the study, interpreting the data, writing, and publishing the report. All of the authors are employed by the state universities associated with the sponsorship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript uses publicly available data from the US Census. IRB approval would be given by the board at NC State University with reliance by Georgia Tech but it is not needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The US Census data that was used is publicly available. The paper also uses disease estimates from the literature. These are clearly outlined in a supplemental file and made available to the readers.
